Combination Therapy with Enzalutamide and Radium-223 in mCRPC: Insights from the REASSURE Study
/ Igle Jan de Jong / Jan Andreasen
ESMO 2025: Paradigm Shift in Breast Cancer Treatment
/ Charles E Geyer Jr.
ESMO 2025: Darolutamide-Treated mHSPC Patients Show a More Durable and Stronger PSA Response vs Abiraterone
/ Alicia Morgans / Jan Andreasen











